



Handwritten signature/initials

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/719,734
Filing Date	November 21, 2003
First Named Inventor	Solomon S. Steiner
Art Unit	1616
Examiner Name	James Henry Alstrum Acevedo
Attorney Docket Number	PDT 120/121 DIV CON

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 14 pages PTO Form-1449; 94 references; and Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Pabst Patent Group LLP		
Signature	<i>Rivka D. Monheit</i>		
Printed name	Rivka D. Monheit		
Date	October 23, 2007	Reg. No.	48,731


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	<i>Peggy McKinney</i>		
Typed or printed name	Peggy McKinney	Date	10/23/07

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/17 (05-07)

Approved for use through 05/31/2007. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).**FEE TRANSMITTAL**
For FY 2007☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 180.00**Complete if Known**

Application Number	10/719,734
Filing Date	November 21, 2003
First Named Inventor	Solomon S. Steiner
Examiner Name	James Henry Alstrum Acevedo
Art Unit	1616
Attorney Docket No.	PDT 120/121 DIV CON

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 50-3129 Deposit Account Name: Pabst Patent Group LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims
_____ - 20 or HP = _____	x _____	= _____		Fee (\$) Fee Paid (\$)

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
_____ - 3 or HP = _____	x _____	= _____	

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____ - 100 = _____	/ 50 = _____	(round up to a whole number) x _____	= _____	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Information Disclosure Statement**Fees Paid (\$)**

\$180.00

SUBMITTED BY

Signature	<u>Rivka D. Monheit</u>	Registration No. (Attorney/Agent) 48,731	Telephone 404-879-2152
Name (Print/Type)	Rivka D. Monheit		Date 10/23/07

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Solomon S. Steiner, Rodney J. Woods, and Joseph W. Sulner

Serial No.: 10/719,734

Art Unit: 1616

Filed: November 21, 2003

Examiner: Alstrum Acevedo, James Henry

For: *PURIFICATION AND STABILIZATION OF PEPTIDE AND PROTEIN
PHARMACEUTICAL AGENTS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

10/25/2007 AAHHADI 00000016 503129 10719734
01 FC:1006 100.00 DA

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including fourteen (14) pages of PTO Form-1449 and copies of the ninety-four (94) documents cited therein. Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003, in 1273 OG 55, copies of U.S. Patents and Published Applications are not enclosed. Copies will be provided upon request, however.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c) after a first Office Action on the merits. The Commissioner is authorized to charge \$180.00, the fee set forth under 37 C.F.R. § 1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should an additional fee be

required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-3129.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
3,906,950	09-23-1975	Cocozza	128/266
3,921,637	11-25-1975	Bennie, et al.	128/266
4,153,689	05-08-1979	Hirai	514/3
4,196,196	04-01-1980	Tiholiz	514/4
4,211,769	07-08-1980	Okada	514/15
4,272,398	06-09-1981	Jaffe	427/213.31
4,294,829	10-13-1981	Suzuki	514/174
4,659,696	04-21-19	Hirai	514/15
4,861,627	08-29-1989	Mathiowitz	427/213.31
4,866,051	09-1989	Hunt	514/180
4,946,828	08-07-1990	Markussen	514/3
5,006,343	04-09-1991	Benson	424/450
5,042,975	08-27-1991	Chien	604/20
5,145,684	09-08-1992	Liversidge, et al.	424/489
5,188,837	02-1993	Domb	424/450
5,204,108	04-20-1993	Illum	424/434
5,260,306	11-09-1993	Boardman, et al.	424/45
5,354,562	10-11-1994	Platz	424/489
5,364,838	11-15-1994	Rubsamen	514/3
5,458,135	10-17-1995	Patton, et al.	128/200.14
5,482,927	01-09-1996	Maniar	514/12
5,484,606	01-16-1996	Dhabar, et al.	424/455
5,492,112	02-20-1996	Mecikalski, et al.	128/203.15
5,514,646	05-07-1996	Chance, et al.	364/556
5,547,929	08-20-1996	Anderson Jr. et al.	514/3
5,562,909	10-08-1996	Allcock, et al.	424/280.1
5,577,497	11-26-1996	Mecikalski, et al.	128/203.15
5,653,961	08/05/1997	McNally, et al.	424/45
5,658,878	08-19-1997	Bäckström, et al.	514/3
5,693,338	12-02-1997	Milstein	424/451
5,740,794	04-21-1998	Smith, et al.	128/203.15
5,747,445	05-05-1998	Bäckström, et al.	514/4
5,763,396	06-09-1998	Weiner, et al.	514/3
5,785,989	07-28-1998	Stanley, et al.	424/440
5,785,049	07-28-1998	Smith, et al.	128/203.15
5,807,315	09-1998	Van Antwerp, et al.	604/502

5,849,322	12-15-1998	Ebert, et al.	424/435
5,874,064	02-23-1999	Edwards, et al.	424/46
5,877,174	03-02-1999	Ono, et al.	514/252
5,901,703	05-11-1999	Ohki, et al.	128/203.12
5,912,011	06-15-1999	Makino, et al.	424/455
5,929,027	07-27-1999	Takama, et al.	514/2
5,952,008	09-14-1999	Bäckström, et al.	424/499
5,985,309	11-16-1999	Edwards, et al.	424/426
5,997,848	12-07-1999	Patton, et al.	424/46
6,051,256	04-18-2000	Platz, et al.	424/489
6,063,910	05-2000	Debenedetti	530/418
6,099,517	09-08-2000	Daughterty	604/514
6,153,613	11-28-2000	Ono, et al.	514/252.13
6,254,854	07-03-2001	Edwards, et al.	424/46
6,294,204	09-25-2001	Rossling, et al.	424/497
6,395,774	05-28-2002	Milstein	514/490
6,423,344	07-23-2002	Platz, et al.	424/491
6,432,383	08-13-2002	Modi	424/43
6,436,443	08-20-2002	Edwards, et al.	424/489
6,440,463	08-27-2002	Feldstein, et al.	424/489
6,447,753	09-10-2002	Edwards, et al.	424/45
6,503,480	01-07-2003	Edwards, et al.	424/45
6,518,239	02-11-2003	Kuo, et al.	514/2
6,592,904	07-15-2003	Platz, et al.	424/491
6,635,283	10-21-2003	Edwards, et al.	424/489
6,676,931	01-13-2004	Dugger, III	424/45
6,582,728	06-24-2003	Platz	
6,685,967	02-03-2003	Patton	424/499
6,737,045	05-18-2004	Patton	424/046
6,949,258	09-24-2005	Zhang	424/451
7,030,084	04-18-2006	Ekwuribe, et al.	424/520
RE35,862	07-28-1998	Steiner, et al.	424/455
RE37,053	02-13-2001	Hanes, et al.	424/489

U.S. Patent Applications

<u>Number</u>	<u>Publication Date</u>	<u>Inventor</u>	<u>Class/Subclass</u>
2003/0064097	04-03-2003	Patel, et al.	424/465
2003/0068378	04-10-2003	Chen, et al.	424/486
2003/0194420	10-16-2003	Holl, et al.	424/426
2004/0151774	08-05-2004	Pauletti, et al.	424/486
2004/0247628	12-09-2004	Lintz, et al.	424/400

U.S.S.N.: 10/719,734

Filed: November 21, 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

2004/157928	08-12-2004	Kim Jae-Hwan, et al. 514/570
2004/0182387	09-23-2004	Steiner
2004/0096403	05-20-2004	Steiner
2003-0017211	01-23-2003	Steiner
2004/0096403	05-20-2004	Steiner
2005/0214251	03-11-2005	Steiner
2005/0080000	04-14-2005	Thurrow Horst, et al. 514/003
2005/0153874	07-14-2005	Cheatham
2007/0086952	09-29-2006	Steiner

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0/069/715	01-12-1983	Draco AB	EP
0/122/036	10-17-1984	Teijin Ltd	EP
0/237/507	09-16-1987	Draco AB	EP
0 257 915	02-03-1988	Innovata Biomed Ltd.	EP
0/360/340	03-28-1990	Akzo	EP
0/364/235	04-18-1990	Toyo Jozo Kabushiki	EP
0/606/486	12-23-1993	Teijin Ltd.	EP
0655237	03-26-1996	Hoechst AG	EP
0748213	12-18-1996	Inhale Therapeutic Sys	EP
1/114/644	07-11-2001	Genetech, Inc.	EP
96911738	06-16-2004	Nektar Therapeutics	EP
2,240,337	07-31-1991	National Research Development Corp.	GB
0149545	02-12-1992	Taisho Pharmaceutical Co.	JP
363020301A	01-1998	Dainichi Color and Chem	JP
0 220 958 A2	05-06-1987	Eli Lilly and Company	PCT
WO 90/13285	11-15-1990	Enzytech, Inc	PCT
WO 91/16882	11-14-1991	Liposome Technology	PCT
WO 91/04011	04-04-1991	Riker Laboratories Inc.	PCT
WO 92/08509	05-29-1992	Minnesota Mining and Manufacturing Company	PCT
WO 93/02712	02-18-1993	Danbiosyst	PCT
WO 92/04069	03-1992	Aktiebolaget astra	PCT
WO 93/17728	09-1993	Aktiebolaget Astra	PCT
WO 93/02712	02-18-1993	Danbiosyst UK Limited	PCT
WO 93/18754	09-30-1993	Pharmaceutical Discovery	PCT
WO 94/000291	01-06-1994	Fisons Plc	PCT
WO 95/00127		Astra Atkiebolag	PCT
WO 95/11666	05-04-1995	Coordinated Drug	PCT

WO 95/31979	11-30-1995	Development Ltd. R.P Scherer International Corporation	PCT
WO 95/34294	12-21-1995	Hamilton, Brook, Smith, & Reynolds P.C. and Yisum Research Development Co. of the Hebrew University of Jerusalem	PCT
WO 97/49386	12-31-1997	Peptide Delivery Systems PTY Ltd.	PCT
WO 01/00654	01-2001	Steiner	PCT
WO 01/07107	02-01-2001	Pharmaceutical Discovery Corporation	PCT
WO 02/11676	02-14-2002	DMI Biosciences, Inc.	PCT
WO 03/057170	07-17-2003	Emisphere Technologies	PCT
WO 03/086345	10-23-2003	Atrix Laboratories, Inc.	PCT
WO 03/094951	11-20-2003	Novo Nordisk As	PCT
WO 04/056314	07-08-2004	Nastech Pharmaceutical Company Inc.	PCT
WO 04/075919	09-10-2004	Medtronic Minimed, Inc	PCT
WO 05/089722	09-29-2005	Biodel Inc.	PCT

Publications

BAUER, et al., "Assessment of beta-adrenergic receptor blockade after isamoltane, a 5-HT1-receptor active compound, in healthy volunteers," *Clin. Pharmacol Ther* 53:76-83 (1993).

BENITA, "Characterization of Drug-Loaded Poly(d,l-lactide) Microspheres," *J. Pharm. Sci.*, 73: 1721-1724 (1984).

BENSCH, et al., "Absorption of intact protein molecules across the pulmonary air-tissue barrier," *Science* 156: 1204-1206 (1967).

BERGE, et al. "Pharmaceutical Salts," *J. Pharmaceutical Sciences* 66(1):1-19 (1997).

BRANGE, et al., "Insulin Structure and stability", *Pharm Biotechnol.*, 5:315-50 (1993).

CEFALU, et al, "Inhaled Human Insulin Treatment in Patients with type 2 diabetes mellitus," *Ann. Int. Med.*, 134: 203-7 (2001).

CHEATHAM and PFEUTZNER, "Desirable dynamics & performance of inhaled insulin compared to subcutaneous insulin given at mealtime in type 2 diabetes: A report from the technosphere/insulin study group" *Diabetes Technology & Therapeutics* 6:234-235 (2004).

COSTELLO, et al., "Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism in prostate epithelial cells", *Journ. Biol. Chem.*, 272(46):28875-28881 (1997).

DIETER KÖHLER, "Aerosols for Systemic Treatment", *Lung (Suppl)*, 677-684 (1990).

DUNN, "Zinc-ligand interactions modulate assembly and stability of the insulin hexamer", *Biometals*, 18(4):295-303 (2005).

ELLIOTT, et al., "Parenteral absorption of insulin from the lung in diabetic children," *Austr. Paediatr. J.* 23: 293-297 (1987).

ENGELGAU, et al., "Screening for type 2 diabetes," *Diabetes Care* 1563(23):1-31 (2000).

FESTA, et al., "LDL particle size in relation to insulin, proinsulin, and insulin sensitivity" *Diabetes Care* 22(10):1688-1693 (1999).

GARBER, "Premixed insulin analogues for the treatment of diabetes mellitus", *Drugs*, 66(1):31-49 (2006).

HAFFNER, et al., "Proinsulin and insulin concentrations in relation to carotid wall thickness" *Stroke* 29:1498-1503 (1998).

HAGEDORN, et al., "Protamine insulin", *JAMA*, 106:177-180 (1936).

HANLEY et al., "Cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors in a population experiencing rapid cultural transition" *Diabetes Care* 24(7):1240-1247 (2001).

HEINEMANN, et al. "Current Status of the development of inhaled insulin" *Br. J. Diabetes Vasc Dis* 4:295-301 (2004).

HEUBNER, et al. *Klinische Wochenschrift* 16,2342 (1924)

HEYDER, "Alveolar deposition of inhaled particles in humans," *Am. Ind. Hyg. Assoc. J.* 43(11): 864-866 (1982).

HEYDER, "Particle Transport onto Human Airway Surfaces" *Eur. J. Respir. Dis. Suppl.* 119, 29-50 (1982)

JOHNSON, et al., "Turbuhaler®: a new device for dry powder terbutaline inhalation," *Allergy* 43(5):392-395 (1988)

KOHLER, et al., "Pulmonary Administration . . .," Abstract 298, *Diabetes* 33 (Suppl.):75A (1984).

KOHLER, "'Aerosols for Systemic Treatment", *Lung Suppl.* 677-683 (1990)

KOHLER, et al. "Non-radioactive approach for measuring lung permeability: inhalation of insulin," *Atemw Lungebkrkh* 13:230-232 (1987). (Original in German and English Translation attached).

KOMADA, et al., "Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung," *J. Pharm. Sci.* 83(6): 863-867 (1994).

KONTNY, et al. "Issues Surrounding MDI Formulation Development with Non-CFC Propellants," *J. Aerosol Med.* 4(3), 181-187 (1991).

LEE, et al., "Development of an Aerosol Dosage Form Containing Insulin," *J. Pharm. Sci.* 65(4), 567-572 (1976).

LIM, "Microencapsulation of Living Cells and Tissues," *J. Pharm. Sci.*, 70: 351-354 (1981).

MATHIOWITZ, "Morphology of Polyanhydride Microsphere Delivery Systems," *Scanning Microscopy*, 4: 329-340 (1990).

MATHIOWITZ, "Novel Microcapsules for Delivery Systems," *Reactive Polymers*, 6: 275-283 (1987).

MATHIOWITZ, "Polyanhydride Microspheres As Drug Carriers I. Hot-Melt Microencapsulation," *J. Controlled Release*, 5: 13-22 (1987).

MATHIOWITZ, "Polyanhydride Microspheres As Drug Carriers II. Microencapsulation by Solvent Removal," *J. Applied Poly. Sci.*, 35: 755-774 (1988).

MATHIOWITZ, "Polyanhydride Microspheres IV. Morphology and Characterization of Systems Made by Spray Drying," *J. Applied Poly. Sci.*, 45: 125-134 (1992).

MOREN, Aerosols in Medicine, (2nd ed.), Elsevier, pp. 321-350.

NAGAI, et al., "Powder Dosage Form of Insulin for Nasal Administration," *J. Control Rel.*, 1:15-22 (1984).

OKUMURA, et al., "Intratracheal delivery of insulin. Absorption from solution and aerosol by rat lung," *Int. J. Pharmaceuticals* 88: 63-73 (1992).

PATTON & PLATZ, "Routes of Delivery: Case Studies. Pulmonary delivery of peptides and proteins for systemic action," *Adv. Drug. Del. Rev.* 8: 179-196 (1992).

PFUTZNER, et al., "Influence of small dose i.v., s.c. and pulmonary insulin treatment on prandial glucose control in patients with type 2 diabetes" *37th Annual Meeting of the EASD, Glasgow, 9-13 September 2001* 812 (2001) (abstract).

PRABHU, et al. "A study of factors controlling dissolution kinetic of zinc complexed protein suspensions in various ionic species", *Int. J. Pharm.*, 217(1-2):71-8 (2001).

RASKIN, et al., "Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes" *Diabetes Care* 26:2598-2603 (2003).

RAZ, et al. "Pharmacodynamic and pharmacokinetics of dose ranging effects of oralin versus s.c. regular insulin in Type 1 diabetic patients," *Fourth Annual Diabetes Technology Meeting*, Philadelphia, PA, 2004.

ROSENSTOCK, et al., "Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes", *Diabetes Care*, 28(4):950-5 (2005).

SALIB, "Utilization of Sodium Alginate in Drug Microencapsulation," *Pharazeutische Industrie* , 40(11a): 1230-1234 (1978).

SAWHNEY, "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(a-hydroxy acid) Diacrylate Macromers," *Macromolecules*, 26: 581-587 (1993).

SCHLUTER, et al., "Pulmonary Administration of Human Insulin in Volunteers and Type I Diabetics", *Diabetes*, 33 (Suppl.): 298 (1984)

SCHNEIDER, et al., "Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells" *Diabetes* 41(7):890-895 (1992).

STEINER, et al. "Technosphere TM/ Insulin- proof of concept study with new insulin formulation for pulmonary delivery" *Exp. Clin. Endocrinol. Diabetes* 110:17-21 (2002).

WARREN, et al., "Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients" *Diabetes Research and Clinical Practive* 66:23-29 (2004).

WATERHOUSE, et al. " Comparative assessment of a new breath-actuated inhaler in patients with reversible airways obstruction." *Respiration* 59:155-158 (1992).

WIGLEY, et al., "Insulin across respiratory mucosae by aerosol delivery," *Diabetes* 20(8): 552-556 (1971).

WIGLEY, et al., "Insulin across respiratory mucosae by aerosol delivery," *Diabetes* 20(8): 552-556 (1971).

WITCHERT, "Low Molecular Weight PLA: A Suitable Polymer for Pulmonary Administered Microparticles," *J. Microencapsulation*, 10(2): 195-207 (1993).


YOSHIDA, et al., "Absorption of insulin delivered to rabbit trachea using aerosol dosage form," *J. Pharm. Sci.* 68(5): 670-671 (1979).

ZETHELIUS, et al., "Proinsulin is an Independent Predictor of Coronary Heart Disease" *Circulation* 105:2153-2158 (2002).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,


Rivka D. Monheit
Reg. No. 48,731

Dated: October 23, 2007

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2152 (Telephone)
(404) 879-2160 (Fax)